Thrivent Financial for Lutherans Sells 64,201 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Thrivent Financial for Lutherans cut its holdings in Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) by 45.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 77,024 shares of the company’s stock after selling 64,201 shares during the quarter. Thrivent Financial for Lutherans owned 0.12% of Kura Oncology worth $956,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Great West Life Assurance Co. Can acquired a new position in shares of Kura Oncology during the third quarter valued at about $39,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Kura Oncology by 38.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,596 shares of the company’s stock valued at $119,000 after purchasing an additional 2,650 shares during the period. Annandale Capital LLC acquired a new position in shares of Kura Oncology during the third quarter valued at about $137,000. ProShare Advisors LLC raised its holdings in shares of Kura Oncology by 11.0% in the 4th quarter. ProShare Advisors LLC now owns 14,009 shares of the company’s stock worth $174,000 after acquiring an additional 1,388 shares during the last quarter. Finally, Bridgefront Capital LLC bought a new position in Kura Oncology in the 1st quarter valued at about $180,000.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Stifel Nicolaus lowered their price target on Kura Oncology from $25.00 to $24.00 in a research report on Thursday, May 11th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a report on Friday, February 24th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 price objective on shares of Kura Oncology in a research note on Monday, April 17th. BTIG Research started coverage on Kura Oncology in a research note on Tuesday, May 16th. They issued a “buy” rating and a $31.00 target price on the stock. Finally, StockNews.com initiated coverage on Kura Oncology in a research report on Thursday, May 18th. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.71.

Kura Oncology Trading Up 4.0 %

Shares of KURA stock opened at $13.93 on Wednesday. The company has a quick ratio of 21.65, a current ratio of 21.65 and a debt-to-equity ratio of 0.02. The firm has a market cap of $953.37 million, a P/E ratio of -6.83 and a beta of 0.89. The company has a 50 day moving average of $11.73 and a 200-day moving average of $12.70. Kura Oncology, Inc. has a 12-month low of $9.49 and a 12-month high of $19.93.

Kura Oncology (NASDAQ:KURA – Get Rating) last released its earnings results on Wednesday, May 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. Sell-side analysts anticipate that Kura Oncology, Inc. will post -2.33 earnings per share for the current year.

Kura Oncology Company Profile

(Get Rating)

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias.